Article(id=1326653054037897306, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326653015873926017, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.01.005, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1731513600000, receivedDateStr=2024-11-14, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228336104, onlineDateStr=2026-11-09, pubDate=1736438400000, pubDateStr=2025-01-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228336104, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228336104, creator=13701087609, updateTime=1794228336104, updator=13701087609, issue=Issue{id=1326653015873926017, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='1', pageStart='1', pageEnd='103', issueExtLink='null', onlineDate='null', pubDate='1736438400000', pubDateStr='2025-01-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228327004, creator='13701087609', updateTime=1794273113022, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840862513935350, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326653015873926017, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840862513935351, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326653015873926017, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=23, endPage=28, ext={EN=ArticleExt(id=1326653055879196764, articleId=1326653054037897306, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress of drugs to reduce whole intact parathyroid hormone in the treatment of chronic kidney disease-mineral and bone disorder, columnId=null, journalTitle=World Clinical Drug, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Secondary hyperparathyroidism(SHPT) is one of the most important complications of chronic kidney disease-mineral and bone disorder(CKD-MBD), which can significantly increase the risk of bone deformities,cardiovascular events, and death. In the current treatment of CKD-MBD SHPT, phosphorus binders, calcium-like agents,polynuclear iron-hydroxide and tenapanor have shown advantages. Novel active vitamin D analogues can effectively reduce the level of intact parathyroid hormone(iPTH). This article reviewed the recent progress of IPTH-decreasing CKD-MBD drugs in order to provide reference for clinical use.

, authors=Qiannan ZHANG1, Niansong WANG2, *, Junhui LI1, *, authorsList=Qiannan ZHANG, Niansong WANG, Junhui LI, authorCompany=null, correspAuthors=Niansong WANG, Junhui LI, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326653056193769565, articleId=1326653054037897306, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=慢性肾脏病-矿物质骨紊乱治疗中降全段甲状旁腺激素药物研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

继发性甲状旁腺功能亢进(secondary hyperparathyroidism,SHPT)是慢性肾脏病-矿物质骨紊乱(chronic kidney disease-mineral and bone disorder,CKD-MBD)的重要并发症之一,可显著增加患者骨骼畸形、心血管事件及死亡的发生风险。在目前CKD-MBD SHPT的临床治疗中,磷结合剂、拟钙剂、多核铁-氢氧化物及tenapanor等药物均展现出一定优势;新型活性维生素D类似物可有效降低全段甲状旁腺激素(intact parathyroid hormone,iPTH)水平。该文对近年来降iPTH CKD的MBD治疗药物进展作一综述,旨在为临床用药提供参考。

, authors=张倩楠1, 汪年松2, *, 李军辉1, *, authorsList=张倩楠, 汪年松, 李军辉, authorCompany=null, correspAuthors=汪年松, 李军辉, authorNote=

张倩楠,主治医师,研究方向:慢性肾脏病的诊治。

, correspAuthorsNote=
汪年松,主任医师,教授,博士生导师,研究方向:糖尿病肾病、急性肾损伤发病机制和防治
李军辉,副主任医师,副教授,研究方向:慢性肾脏病诊治。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=8QsTpc/+oSUqsUvVj9F80Q==, magXml=tth28Qz1dCHGltjOMK3MRg==, pdfUrl=null, pdf=Z02f/vxViYPT9ulkecdfVA==, pdfFileSize=921122, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=8CHAKnKMGsyantziSNuOmw==, mapNumber=null, fund=null)}, authors=[Author(id=1326653056609005669, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326653056688697447, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653056609005669, language=EN, stringName=Qiannan ZHANG, firstName=Qiannan, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Nephrology, Tongji University Affiliated Putuo People's Hospital, Shanghai 200060, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326653056747417704, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653056609005669, language=CN, stringName=张倩楠, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.同济大学附属普陀人民医院肾内科,上海 200060, bio={"content":"

张倩楠,主治医师,研究方向:慢性肾脏病的诊治。

"}, bioImg=null, bioContent=

张倩楠,主治医师,研究方向:慢性肾脏病的诊治。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326653056390901854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, xref=1., ext=[AuthorCompanyExt(id=1326653056403484767, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056390901854, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Nephrology, Tongji University Affiliated Putuo People's Hospital, Shanghai 200060, China), AuthorCompanyExt(id=1326653056411873376, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056390901854, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.同济大学附属普陀人民医院肾内科,上海 200060)])]), Author(id=1326653056910995562, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326653057011658860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653056910995562, language=EN, stringName=Niansong WANG, firstName=Niansong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326653057154265197, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653056910995562, language=CN, stringName=汪年松, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.上海交通大学医学院附属第六人民医院肾内科,上海 200233, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326653056537702497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, xref=2., ext=[AuthorCompanyExt(id=1326653056541896802, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056537702497, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China), AuthorCompanyExt(id=1326653056550285411, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056537702497, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海交通大学医学院附属第六人民医院肾内科,上海 200233)])]), Author(id=1326653057217179759, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326653057326231665, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653057217179759, language=EN, stringName=Junhui LI, firstName=Junhui, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Department of Nephrology, Tongji University Affiliated Putuo People's Hospital, Shanghai 200060, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326653057410117746, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653057217179759, language=CN, stringName=李军辉, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.同济大学附属普陀人民医院肾内科,上海 200060, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326653056390901854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, xref=1., ext=[AuthorCompanyExt(id=1326653056403484767, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056390901854, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Nephrology, Tongji University Affiliated Putuo People's Hospital, Shanghai 200060, China), AuthorCompanyExt(id=1326653056411873376, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056390901854, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.同济大学附属普陀人民医院肾内科,上海 200060)])])], keywords=[Keyword(id=1326653057611444339, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, language=EN, orderNo=1, keyword=chronic kidney disease-mineral bone disorder), Keyword(id=1326653057686941812, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, language=EN, orderNo=2, keyword=secondary hyperparathyroidism), Keyword(id=1326653057833742453, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, language=EN, orderNo=3, keyword=whole intact parathyroid hormone), Keyword(id=1326653057946988662, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, language=CN, orderNo=1, keyword=慢性肾脏病-矿物质骨紊乱), Keyword(id=1326653058056040567, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, language=CN, orderNo=2, keyword=继发性甲状旁腺功能亢进症), Keyword(id=1326653058118955128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, language=CN, orderNo=3, keyword=全段甲状旁腺激素)], refs=[Reference(id=1326653058433527931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=中华预防医学会肾脏病预防与控制专业委员会. 中国慢性肾脏病早期评价与管理指南[J]. 中华内科杂志, 2023,62(8): 902-930., articleTitle=null, refAbstract=null), Reference(id=1326653058504831100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=MOE S, DRUEKE T, CUNNINGHAM J, et al. Eknoyan,definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease:Improving Global Outcomes(KDIGO)[J]. Kidney Int, 2006,69(11): 1945-1953., articleTitle=null, refAbstract=null), Reference(id=1326653060228690045, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=国家肾脏疾病临床医学研究中心. 中国慢性肾脏病矿物质和骨异常诊治指南概要[J]. 肾脏病与透析肾移植杂志,2019, 28(1): 52-57., articleTitle=null, refAbstract=null), Reference(id=1326653060291604606, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=TSAI SH, KAN WC, JHEN RN, et al. Secondary hyperparathyroidism in chronic kidney disease: a narrative review focus on therapeutic strategy[J]. Clin Med(Lond),2024, 24(5): 100238., articleTitle=null, refAbstract=null), Reference(id=1326653060400656511, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=EVENEPOEL P, JORGENSEN HS, KOMABA H, et al.Lower bone turnover and skeletal PTH responsiveness in Japanese compared to European patients on hemodialysis[J].J Clin Endocrinol Metab, 2022, 107(12): e4350-e4359., articleTitle=null, refAbstract=null), Reference(id=1326653060492931200, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=BILEZIKIAN JP, KHAN AA, SILVERBERG SJ, et al.Evaluation and management of primary hyperparathyroidism:summary statement and guidelines from the fifth international workshop[J]. J Bone Miner Res, 2022, 37(11): 2293-2314., articleTitle=null, refAbstract=null), Reference(id=1326653060576817281, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=VIA REQUE CORTES DDP, DRUEKE TB, MOYSES RMA.Persistent uncertainties in optimal treatment approaches of secondary hyperparathyroidism and hyperphosphatemia in patients with chronic kidney disease[J]. Curr Osteoporos Rep, 2024, 22(5): 441-457., articleTitle=null, refAbstract=null), Reference(id=1326653060685869186, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=COZZOLINO M, MANGANO M, STUCCHI A, et al.Cardiovascular disease in dialysis patients[J]. Nephrol Dial Transplant, 2018, 33(suppl_3): iii28-iii34., articleTitle=null, refAbstract=null), Reference(id=1326653060752978052, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=JAMAL SA, VANDERMEER B, RAGGI P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis[J]. Lancet,2013, 382(9900): 1268-1277., articleTitle=null, refAbstract=null), Reference(id=1326653060857835653, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=OGATA H, FUKAGAWA M, HIRAKATA H, et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK randomized clinical trial[J]. J Am Med Assoc,2021, 325(19): 1946-1954., articleTitle=null, refAbstract=null), Reference(id=1326653060954304646, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=SUKI WN, ZABANEH R, CANGIANO JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients[J]. Kidney Int, 2007, 72(9): 1130-1137., articleTitle=null, refAbstract=null), Reference(id=1326653061075939463, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=SPOENDLIN J, PAIK JM, TSACOGIANIS T, et al.Cardiovascular outcomes of calcium-free vs calcium-based phosphate binders in patients 65 years or older with end-stage renal disease requiring hemodialysis[J]. J Am Med Assoc Intern Med, 2019, 179(6): 741-749., articleTitle=null, refAbstract=null), Reference(id=1326653061151436936, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=ISAKOVA T, GUTIERREZ OM, CHANG Y, et al.Phosphorus binders and survival on hemodialysis[J]. J Am Soc Nephrol, 2009, 20(2): 388-396., articleTitle=null, refAbstract=null), Reference(id=1326653061226934409, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=ST PETER WL, LIU J, WEINHANDL E, et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis:a secondary analysis of the Dialysis Clinical Outcomes Revisited(DCOR) randomized trial using claims data[J]. Am J Kidney Dis, 2008, 51(3): 445-454., articleTitle=null, refAbstract=null), Reference(id=1326653061331792010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=DI IORIO B, MOLONY D, BELL C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial[J]. Am J Kidney Dis, 2013, 62(4): 771-778., articleTitle=null, refAbstract=null), Reference(id=1326653061415678091, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=OLIVEIRA RB, CANCELA AL, GRACIOLLI FG, et al.Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?[J]. Clin J Am Soc Nephrol, 2010, 5(2): 286-291., articleTitle=null, refAbstract=null), Reference(id=1326653061541507212, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=TOUSSAINT ND, LAU KK, POLKINGHORNE KR, et al.Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial[J]. Nephrology(Carlton),2011, 16(3): 290-298., articleTitle=null, refAbstract=null), Reference(id=1326653061633781901, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=DAMMENT SJ, PENNICK M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate[J]. Clin Pharmacokinet, 2008, 47(9): 553-563., articleTitle=null, refAbstract=null), Reference(id=1326653061705085070, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=IWAMURO M, URATA H, TANAKA T, et al. Review of the diagnosis of gastrointestinal lanthanum deposition[J]. World J Gastroenterol, 2020, 26(13): 1439-1449., articleTitle=null, refAbstract=null), Reference(id=1326653061767999631, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=PAI AB, JANG SM, WEGRZYN N. Iron-based phosphate binders - a new element in management of hyperphosphatemia[J]. Expert Opin Drug Metab Toxicol,2016, 12(1): 115-127., articleTitle=null, refAbstract=null), Reference(id=1326653061839302800, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=YOKOYAMA K, HIRAKATA H, AKIBA T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD[J]. Clin J Am Soc Nephrol,2014, 9(3): 543-552., articleTitle=null, refAbstract=null), Reference(id=1326653061918994577, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=LEWIS JB, SIKA M, KOURY MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis[J]. J Am Soc Nephrol, 2015, 26(2): 493-503., articleTitle=null, refAbstract=null), Reference(id=1326653061998686354, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=GAN L, XING L, XU Y, et al. Tenapanor in Chinese ESRD patients with hyperphosphatemia on haemodialysis: a randomised, phase 3 trial[J]. Clin Kidney J, 2023, 17(1):sfad216., articleTitle=null, refAbstract=null), Reference(id=1326653062086766739, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=YEUNG WG, PALMER SC, STRIPPOLI GFM, et al.Vitamin D therapy in adults with CKD: a systematic review and meta-analysis[J]. Am J Kidney Dis, 2023, 82(5): 543-558., articleTitle=null, refAbstract=null), Reference(id=1326653062153875604, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=BRICKMAN AS, COBURN JW, NORMAN AW. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3, in uremic man[J]. N Engl J Med,1972, 287(18): 891-895., articleTitle=null, refAbstract=null), Reference(id=1326653062212595861, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=MADSEN S, OLGAARD K, LADEFOGED J. Direct feed-back regulation of PTH-secretion by 1,25-dihydroxyvitamin D3 in renal failure: a controlled trial[J]. Proc Eur Dial Transplant Assoc, 1980, 17: 557-562., articleTitle=null, refAbstract=null), Reference(id=1326653062279704726, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=SPRAGUE SM, LLACH F, AMDAHL M, et al.Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism[J]. Kidney Int, 2003, 63(4): 1483-1490., articleTitle=null, refAbstract=null), Reference(id=1326653062346813591, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=TENG M, WOLF M, LOWRIE E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy[J]. N Engl J Med, 2003, 349(5): 446-456., articleTitle=null, refAbstract=null), Reference(id=1326653062405533848, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=COBURN JW, MAUNG HM, ELANGOVAN L, et al.Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4[J]. Am J Kidney Dis, 2004,43(5): 877-890., articleTitle=null, refAbstract=null), Reference(id=1326653062493614233, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=FRAZAO JM, ELANGOVAN L, MAUNG HM, et al.Intermittent doxercalciferol(1α-hydroxyvitamin D(2))therapy for secondary hyperparathyroidism[J]. Am J Kidney Dis, 2000, 36(3): 550-561., articleTitle=null, refAbstract=null), Reference(id=1326653062652997786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=BLOCK GA, MARTIN KJ, DE FRANCISCO AL, et al.Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis[J]. N Engl J Med, 2004, 350(15):1516-1525., articleTitle=null, refAbstract=null), Reference(id=1326653062741078171, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=CHERTOW GM, BLOCK GA, CORREA-ROTTER R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis[J]. N Engl J Med, 2012, 367(26): 2482-2494., articleTitle=null, refAbstract=null), Reference(id=1326653062812381340, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=PARFREY PS, DRUEKE TB, BLOCK GA, et al. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events(EVOLVE) trial[J]. Clin J Am Soc Nephrol, 2015, 10(5): 791-799., articleTitle=null, refAbstract=null), Reference(id=1326653062875295901, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=WHEELER DC, LONDON GM, PARFREY PS, et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events(EVOLVE) trial[J]. J Am Heart Assoc, 2014, 3(6):e001363., articleTitle=null, refAbstract=null), Reference(id=1326653063005319326, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=BLOCK GA, BUSHINSKY DA, CUNNINGHAM J, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials[J]. J Am Med Assoc, 2017, 317(2): 146-155., articleTitle=null, refAbstract=null), Reference(id=1326653064251027615, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=BLOCK GA, BUSHINSKY DA, CHENG S, et al.Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial[J]. J Am Med Assoc, 2017, 317(2): 156-164., articleTitle=null, refAbstract=null), Reference(id=1326653064313942176, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=FUKAGAWA M, SHIMAZAKI R, AKIZAWA T.Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism[J]. Kidney Int, 2018, 94(4): 818-825., articleTitle=null, refAbstract=null), Reference(id=1326653064439771297, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=EVENEPOEL P, STENVINKEL P, SHANAHAN C, et al.Inflammation and gut dysbiosis as drivers of CKD-MBD[J].Nat Rev Nephrol, 2023, 19(10): 646-657., articleTitle=null, refAbstract=null), Reference(id=1326653064536240290, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=BIRUETE A, SHIN A, KISTLER BM, et al. Feeling gutted in chronic kidney disease(CKD): gastrointestinal disorders and therapies to improve gastrointestinal health in individuals CKD, including those undergoing dialysis[J]. Semin Dial,2024, 37(4): 334-349., articleTitle=null, refAbstract=null), Reference(id=1326653064699818147, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=SAAOUD F, LIU L, XU K, et al. Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways[J].JCI Insight, 2023, 8(1): e158183., articleTitle=null, refAbstract=null), Reference(id=1326653064775315620, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=JAFARNEJAD S, DJAFARIAN K, FAZELI MR, et al.Effects of a multispecies probiotic supplement on bone health in osteopenic postmenopausal women: a randomized, double-blind, controlled trial[J]. J Am Coll Nutr, 2017, 36(7): 497-506., articleTitle=null, refAbstract=null), Reference(id=1326653064842424485, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG J, MOTYL KJ, IRWIN R, et al. Loss of bone and Wnt10b expression in male type 1 diabetic mice is blocked by the probiotic lactobacillus reuteri[J]. Endocrinology, 2015,156(9): 3169-3182., articleTitle=null, refAbstract=null), Reference(id=1326653064930504870, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=BIRUETE A, CHEN NX, METZGER CE, et al. The dietary fiber inulin slows progression of chronic kidney disease-mineral and bone disorder(CKD-MBD) in a rat model of CKD[J]. JBMR Plus, 2023, 7(12): e10837., articleTitle=null, refAbstract=null)], funds=[Fund(id=1326653058244784249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, awardId=ptkwws202412, language=CN, fundingSource=上海市普陀区科委课题(ptkwws202412), fundOrder=null, country=null), Fund(id=1326653058316087418, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, awardId=2022rmky12, language=CN, fundingSource=上海市普陀区人民医院院级课题(2022rmky12), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1326653056390901854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, xref=1., ext=[AuthorCompanyExt(id=1326653056403484767, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056390901854, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Nephrology, Tongji University Affiliated Putuo People's Hospital, Shanghai 200060, China), AuthorCompanyExt(id=1326653056411873376, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056390901854, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.同济大学附属普陀人民医院肾内科,上海 200060)]), AuthorCompany(id=1326653056537702497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, xref=2., ext=[AuthorCompanyExt(id=1326653056541896802, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056537702497, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China), AuthorCompanyExt(id=1326653056550285411, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056537702497, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海交通大学医学院附属第六人民医院肾内科,上海 200233)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.01.005, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.01.005, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.01.005, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.01.005, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1736438400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
慢性肾脏病-矿物质骨紊乱治疗中降全段甲状旁腺激素药物研究进展
张倩楠 1 , 汪年松 2, * , 李军辉 1, *
世界临床药物 | 医药专论 2025,46(1): 23-28
收起
收藏切换
世界临床药物 |医药专论 2025 , 46 (1) : 23 -28
慢性肾脏病-矿物质骨紊乱治疗中降全段甲状旁腺激素药物研究进展
全屏
[Author(id=1326653056609005669, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326653056688697447, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653056609005669, language=EN, stringName=Qiannan ZHANG, firstName=Qiannan, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Nephrology, Tongji University Affiliated Putuo People's Hospital, Shanghai 200060, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326653056747417704, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653056609005669, language=CN, stringName=张倩楠, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.同济大学附属普陀人民医院肾内科,上海 200060, bio={"content":"

张倩楠,主治医师,研究方向:慢性肾脏病的诊治。

"}, bioImg=null, bioContent=

张倩楠,主治医师,研究方向:慢性肾脏病的诊治。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326653056390901854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, xref=1., ext=[AuthorCompanyExt(id=1326653056403484767, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056390901854, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Nephrology, Tongji University Affiliated Putuo People's Hospital, Shanghai 200060, China), AuthorCompanyExt(id=1326653056411873376, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056390901854, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.同济大学附属普陀人民医院肾内科,上海 200060)])]), Author(id=1326653056910995562, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326653057011658860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653056910995562, language=EN, stringName=Niansong WANG, firstName=Niansong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326653057154265197, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653056910995562, language=CN, stringName=汪年松, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.上海交通大学医学院附属第六人民医院肾内科,上海 200233, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326653056537702497, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, xref=2., ext=[AuthorCompanyExt(id=1326653056541896802, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056537702497, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China), AuthorCompanyExt(id=1326653056550285411, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056537702497, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海交通大学医学院附属第六人民医院肾内科,上海 200233)])]), Author(id=1326653057217179759, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326653057326231665, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653057217179759, language=EN, stringName=Junhui LI, firstName=Junhui, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Department of Nephrology, Tongji University Affiliated Putuo People's Hospital, Shanghai 200060, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326653057410117746, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, authorId=1326653057217179759, language=CN, stringName=李军辉, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.同济大学附属普陀人民医院肾内科,上海 200060, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326653056390901854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, xref=1., ext=[AuthorCompanyExt(id=1326653056403484767, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056390901854, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Nephrology, Tongji University Affiliated Putuo People's Hospital, Shanghai 200060, China), AuthorCompanyExt(id=1326653056411873376, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326653054037897306, companyId=1326653056390901854, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.同济大学附属普陀人民医院肾内科,上海 200060)])])]
张倩楠1, 汪年松2, *, 李军辉1, *
作者信息
  • 1.同济大学附属普陀人民医院肾内科,上海 200060
  • 2.上海交通大学医学院附属第六人民医院肾内科,上海 200233
通讯作者:
汪年松,主任医师,教授,博士生导师,研究方向:糖尿病肾病、急性肾损伤发病机制和防治
李军辉,副主任医师,副教授,研究方向:慢性肾脏病诊治。
作者简介:

张倩楠,主治医师,研究方向:慢性肾脏病的诊治。

Research progress of drugs to reduce whole intact parathyroid hormone in the treatment of chronic kidney disease-mineral and bone disorder
Qiannan ZHANG1, Niansong WANG2, *, Junhui LI1, *
Affiliations
  • 1.Department of Nephrology, Tongji University Affiliated Putuo People's Hospital, Shanghai 200060, China
  • 2.Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China
出版时间: 2025-01-10 doi: 10.13683/j.wph.2025.01.005
文章导航
收藏切换

继发性甲状旁腺功能亢进(secondary hyperparathyroidism,SHPT)是慢性肾脏病-矿物质骨紊乱(chronic kidney disease-mineral and bone disorder,CKD-MBD)的重要并发症之一,可显著增加患者骨骼畸形、心血管事件及死亡的发生风险。在目前CKD-MBD SHPT的临床治疗中,磷结合剂、拟钙剂、多核铁-氢氧化物及tenapanor等药物均展现出一定优势;新型活性维生素D类似物可有效降低全段甲状旁腺激素(intact parathyroid hormone,iPTH)水平。该文对近年来降iPTH CKD的MBD治疗药物进展作一综述,旨在为临床用药提供参考。

慢性肾脏病-矿物质骨紊乱  /  继发性甲状旁腺功能亢进症  /  全段甲状旁腺激素

Secondary hyperparathyroidism(SHPT) is one of the most important complications of chronic kidney disease-mineral and bone disorder(CKD-MBD), which can significantly increase the risk of bone deformities,cardiovascular events, and death. In the current treatment of CKD-MBD SHPT, phosphorus binders, calcium-like agents,polynuclear iron-hydroxide and tenapanor have shown advantages. Novel active vitamin D analogues can effectively reduce the level of intact parathyroid hormone(iPTH). This article reviewed the recent progress of IPTH-decreasing CKD-MBD drugs in order to provide reference for clinical use.

chronic kidney disease-mineral bone disorder  /  secondary hyperparathyroidism  /  whole intact parathyroid hormone
张倩楠, 汪年松, 李军辉. 慢性肾脏病-矿物质骨紊乱治疗中降全段甲状旁腺激素药物研究进展. 世界临床药物, 2025 , 46 (1) : 23 -28 . DOI: 10.13683/j.wph.2025.01.005
Qiannan ZHANG, Niansong WANG, Junhui LI. Research progress of drugs to reduce whole intact parathyroid hormone in the treatment of chronic kidney disease-mineral and bone disorder[J]. World Clinical Drug, 2025 , 46 (1) : 23 -28 . DOI: 10.13683/j.wph.2025.01.005
  • 上海市普陀区科委课题(ptkwws202412)
  • 上海市普陀区人民医院院级课题(2022rmky12)
参考文献 引证文献
排序方式:
[1]
中华预防医学会肾脏病预防与控制专业委员会. 中国慢性肾脏病早期评价与管理指南[J]. 中华内科杂志, 2023,62(8): 902-930.
[2]
MOE S, DRUEKE T, CUNNINGHAM J, et al. Eknoyan,definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease:Improving Global Outcomes(KDIGO)[J]. Kidney Int, 2006,69(11): 1945-1953.
[3]
国家肾脏疾病临床医学研究中心. 中国慢性肾脏病矿物质和骨异常诊治指南概要[J]. 肾脏病与透析肾移植杂志,2019, 28(1): 52-57.
[4]
TSAI SH, KAN WC, JHEN RN, et al. Secondary hyperparathyroidism in chronic kidney disease: a narrative review focus on therapeutic strategy[J]. Clin Med(Lond),2024, 24(5): 100238.
[5]
EVENEPOEL P, JORGENSEN HS, KOMABA H, et al.Lower bone turnover and skeletal PTH responsiveness in Japanese compared to European patients on hemodialysis[J].J Clin Endocrinol Metab, 2022, 107(12): e4350-e4359.
[6]
BILEZIKIAN JP, KHAN AA, SILVERBERG SJ, et al.Evaluation and management of primary hyperparathyroidism:summary statement and guidelines from the fifth international workshop[J]. J Bone Miner Res, 2022, 37(11): 2293-2314.
[7]
VIA REQUE CORTES DDP, DRUEKE TB, MOYSES RMA.Persistent uncertainties in optimal treatment approaches of secondary hyperparathyroidism and hyperphosphatemia in patients with chronic kidney disease[J]. Curr Osteoporos Rep, 2024, 22(5): 441-457.
[8]
COZZOLINO M, MANGANO M, STUCCHI A, et al.Cardiovascular disease in dialysis patients[J]. Nephrol Dial Transplant, 2018, 33(suppl_3): iii28-iii34.
[9]
JAMAL SA, VANDERMEER B, RAGGI P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis[J]. Lancet,2013, 382(9900): 1268-1277.
[10]
OGATA H, FUKAGAWA M, HIRAKATA H, et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK randomized clinical trial[J]. J Am Med Assoc,2021, 325(19): 1946-1954.
[11]
SUKI WN, ZABANEH R, CANGIANO JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients[J]. Kidney Int, 2007, 72(9): 1130-1137.
[12]
SPOENDLIN J, PAIK JM, TSACOGIANIS T, et al.Cardiovascular outcomes of calcium-free vs calcium-based phosphate binders in patients 65 years or older with end-stage renal disease requiring hemodialysis[J]. J Am Med Assoc Intern Med, 2019, 179(6): 741-749.
[13]
ISAKOVA T, GUTIERREZ OM, CHANG Y, et al.Phosphorus binders and survival on hemodialysis[J]. J Am Soc Nephrol, 2009, 20(2): 388-396.
[14]
ST PETER WL, LIU J, WEINHANDL E, et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis:a secondary analysis of the Dialysis Clinical Outcomes Revisited(DCOR) randomized trial using claims data[J]. Am J Kidney Dis, 2008, 51(3): 445-454.
[15]
DI IORIO B, MOLONY D, BELL C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial[J]. Am J Kidney Dis, 2013, 62(4): 771-778.
[16]
OLIVEIRA RB, CANCELA AL, GRACIOLLI FG, et al.Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?[J]. Clin J Am Soc Nephrol, 2010, 5(2): 286-291.
[17]
TOUSSAINT ND, LAU KK, POLKINGHORNE KR, et al.Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial[J]. Nephrology(Carlton),2011, 16(3): 290-298.
[18]
DAMMENT SJ, PENNICK M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate[J]. Clin Pharmacokinet, 2008, 47(9): 553-563.
[19]
IWAMURO M, URATA H, TANAKA T, et al. Review of the diagnosis of gastrointestinal lanthanum deposition[J]. World J Gastroenterol, 2020, 26(13): 1439-1449.
[20]
PAI AB, JANG SM, WEGRZYN N. Iron-based phosphate binders - a new element in management of hyperphosphatemia[J]. Expert Opin Drug Metab Toxicol,2016, 12(1): 115-127.
[21]
YOKOYAMA K, HIRAKATA H, AKIBA T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD[J]. Clin J Am Soc Nephrol,2014, 9(3): 543-552.
[22]
LEWIS JB, SIKA M, KOURY MJ, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis[J]. J Am Soc Nephrol, 2015, 26(2): 493-503.
[23]
GAN L, XING L, XU Y, et al. Tenapanor in Chinese ESRD patients with hyperphosphatemia on haemodialysis: a randomised, phase 3 trial[J]. Clin Kidney J, 2023, 17(1):sfad216.
[24]
YEUNG WG, PALMER SC, STRIPPOLI GFM, et al.Vitamin D therapy in adults with CKD: a systematic review and meta-analysis[J]. Am J Kidney Dis, 2023, 82(5): 543-558.
[25]
BRICKMAN AS, COBURN JW, NORMAN AW. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3, in uremic man[J]. N Engl J Med,1972, 287(18): 891-895.
[26]
MADSEN S, OLGAARD K, LADEFOGED J. Direct feed-back regulation of PTH-secretion by 1,25-dihydroxyvitamin D3 in renal failure: a controlled trial[J]. Proc Eur Dial Transplant Assoc, 1980, 17: 557-562.
[27]
SPRAGUE SM, LLACH F, AMDAHL M, et al.Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism[J]. Kidney Int, 2003, 63(4): 1483-1490.
[28]
TENG M, WOLF M, LOWRIE E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy[J]. N Engl J Med, 2003, 349(5): 446-456.
[29]
COBURN JW, MAUNG HM, ELANGOVAN L, et al.Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4[J]. Am J Kidney Dis, 2004,43(5): 877-890.
[30]
FRAZAO JM, ELANGOVAN L, MAUNG HM, et al.Intermittent doxercalciferol(1α-hydroxyvitamin D(2))therapy for secondary hyperparathyroidism[J]. Am J Kidney Dis, 2000, 36(3): 550-561.
[31]
BLOCK GA, MARTIN KJ, DE FRANCISCO AL, et al.Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis[J]. N Engl J Med, 2004, 350(15):1516-1525.
[32]
CHERTOW GM, BLOCK GA, CORREA-ROTTER R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis[J]. N Engl J Med, 2012, 367(26): 2482-2494.
[33]
PARFREY PS, DRUEKE TB, BLOCK GA, et al. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events(EVOLVE) trial[J]. Clin J Am Soc Nephrol, 2015, 10(5): 791-799.
[34]
WHEELER DC, LONDON GM, PARFREY PS, et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events(EVOLVE) trial[J]. J Am Heart Assoc, 2014, 3(6):e001363.
[35]
BLOCK GA, BUSHINSKY DA, CUNNINGHAM J, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials[J]. J Am Med Assoc, 2017, 317(2): 146-155.
[36]
BLOCK GA, BUSHINSKY DA, CHENG S, et al.Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial[J]. J Am Med Assoc, 2017, 317(2): 156-164.
[37]
FUKAGAWA M, SHIMAZAKI R, AKIZAWA T.Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism[J]. Kidney Int, 2018, 94(4): 818-825.
[38]
EVENEPOEL P, STENVINKEL P, SHANAHAN C, et al.Inflammation and gut dysbiosis as drivers of CKD-MBD[J].Nat Rev Nephrol, 2023, 19(10): 646-657.
[39]
BIRUETE A, SHIN A, KISTLER BM, et al. Feeling gutted in chronic kidney disease(CKD): gastrointestinal disorders and therapies to improve gastrointestinal health in individuals CKD, including those undergoing dialysis[J]. Semin Dial,2024, 37(4): 334-349.
[40]
SAAOUD F, LIU L, XU K, et al. Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways[J].JCI Insight, 2023, 8(1): e158183.
[41]
JAFARNEJAD S, DJAFARIAN K, FAZELI MR, et al.Effects of a multispecies probiotic supplement on bone health in osteopenic postmenopausal women: a randomized, double-blind, controlled trial[J]. J Am Coll Nutr, 2017, 36(7): 497-506.
[42]
ZHANG J, MOTYL KJ, IRWIN R, et al. Loss of bone and Wnt10b expression in male type 1 diabetic mice is blocked by the probiotic lactobacillus reuteri[J]. Endocrinology, 2015,156(9): 3169-3182.
[43]
BIRUETE A, CHEN NX, METZGER CE, et al. The dietary fiber inulin slows progression of chronic kidney disease-mineral and bone disorder(CKD-MBD) in a rat model of CKD[J]. JBMR Plus, 2023, 7(12): e10837.
2025年第46卷第1期
57
14
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.01.005
  • 接收时间:2024-11-14
  • 首发时间:2026-11-09
  • 出版时间:2025-01-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-11-14
基金
上海市普陀区科委课题(ptkwws202412)
上海市普陀区人民医院院级课题(2022rmky12)
作者信息
    1.同济大学附属普陀人民医院肾内科,上海 200060
    2.上海交通大学医学院附属第六人民医院肾内科,上海 200233

通讯作者:

汪年松,主任医师,教授,博士生导师,研究方向:糖尿病肾病、急性肾损伤发病机制和防治
李军辉,副主任医师,副教授,研究方向:慢性肾脏病诊治。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.01.005
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏